Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aurora Cannabis (TSX:ACB) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Aurora Cannabis Forward PE Ratio Related Terms
Aurora Cannabis Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Aurora Cannabis's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurora Cannabis Forward PE Ratio Chart
Aurora Cannabis Annual Data
Trend
2017-06
2018-06
2019-06
2025-03
2026-03
Forward PE Ratio
28.82
263.16
526.32
16.86
55.88
Aurora Cannabis Quarterly Data
2016-12
2017-03
2017-06
2017-09
2018-03
2018-06
2018-09
2019-03
2019-06
2024-12
2025-03
2025-06
2025-12
2026-03
Forward PE Ratio
114.94
34.36
28.82
555.56
92.59
263.16
294.12
92.59
526.32
615.00
16.86
17.20
16.29
55.88
TSX:ACB vs ZTS, UTHR: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aurora Cannabis's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurora Cannabis Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aurora Cannabis's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Aurora Cannabis's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Aurora Cannabis (TSX:ACB) has a Forward PE Ratio of 337.50 as of Jul. 18, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Aurora Cannabis and its competitors. According to the industry distribution chart, Aurora Cannabis ranks #405 out of 410 companies in the Drug Manufacturers industry, placing it in the top 98.8%.
Is Aurora Cannabis' Forward PE Ratio too high?
Aurora Cannabis' current Forward PE Ratio is 337.50. The Drug Manufacturers industry median Forward PE Ratio is 17.27. Aurora Cannabis' value of 337.50 is 1854.8% above this industry median. Based on the distribution chart, Aurora Cannabis ranks #405 out of 410 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Aurora Cannabis has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Aurora Cannabis' Forward PE Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aurora Cannabis ranks #405 out of 410 companies for Forward PE Ratio. This places Aurora Cannabis in the lower half of its industry. The industry median Forward PE Ratio is 17.27. Aurora Cannabis' value of 337.50 is 1854.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.27, based on 410 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurora Cannabis's current Forward PE Ratio of 337.50 is 1854.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Aurora Cannabis and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurora Cannabis's current Forward PE Ratio is 337.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurora Cannabis stock overvalued right now?
Based on GuruFocus' analysis, Aurora Cannabis (TSX:ACB) is currently considered Possible Value Trap. The stock's GF Value™ is C$5.92, compared to a current price of C$3.70 — trading 37.5% below its estimated fair value. The current Forward PE Ratio is 337.50 and 1854.8% above the Drug Manufacturers industry median of 17.27. Aurora Cannabis' overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Aurora Cannabis (TSX:ACB), the current Forward PE Ratio is 337.50 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurora Cannabis (TSX:ACB) Overvalued in 2026?
Based on GuruFocus' analysis, Aurora Cannabis stock appears to be undervalued.
The current stock price of C$3.70 is trading 37.5% below its estimated GF Value™ of C$5.92.
GuruFocus considers Aurora Cannabis to be Possible Value Trap.
Key valuation signals for TSX:ACB:
Forward PE Ratio: 337.50
GF Value™: C$5.92 vs. price of C$3.70 (37.5% below fair value)
Industry Position: 1854.8% above the Drug Manufacturers median (#405 of 410)
No single metric tells the full story. See the TSX:ACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.
49GF Score
Get the complete analysis for TSX:ACB
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:ACB has been successfully added to your 
